Accurate and rapid pre-event testing to safely reopen cultural, sports and leisure events
Pre-event testing is necessary to reduce risks of positive Covid-19 cases at events so that more activities can resume safely.
Pre-event testing for COVID-19 helps to reduce the risk of potentially infectious individuals transmitting the virus at an event, reducing the likelihood of an outbreak situation.
Uncompromised rapid testing with the LumiraDx Platform delivers fast, accurate antigen testing to give organizers the assurance they need that.
a) They can identify potentially contagious spreaders pre-event
b) Attendees can easily and quickly be tested in advance of the event
LumiraDx provides a range of testing solutions:
- Rapid and connected test results in minutes
- Portable and flexible solutions for on or off-site testing setup
- Affordable and scalable testing
#Negative results do not rule out SARS-CoV-2 infection and should be considered in the context of an individual’s recent exposures, history and presence of clinical signs and symptoms consistent with COVID-19. Results should not be used as the sole basis for treatment or case management decisions, including infection control decisions
**Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status
SARS-CoV-2 Pool Test
- Test up to 5 people using 1 test
- Maximise resources and scale up testing: Pooled testing can improve access to testing by significantly reducing resources (tests, operators, instruments) required on a per patient basis
- Save time and cost: Pooled testing can result in savings in both time and cost
1: Michael J. Mina, etal., Rethinking Covid-19 Test Sensitivity — A Strategy for Containment, N Engl J Med 2020; 383:e120
2: Report of the „Bundesamt für Gesundheit“ Switzerland 2020 (available upon request)
3: Kohmer et al., 2021. J Clin Med Jan 17;10(2):328.
4: Krüger et al., 2021 (https://www.medrxiv.org/content/10.1101/2021.03.02.21252430v1)
6: Drain PK, Ampajwala M, Chappel C, et al. A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infect Dis Ther. 2021;10(2):753-761.
7: Linares et al, Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms, J Clin Virol. 2020 Dec; 133: 104659
8: Gannon C.K. Mak, Stephen S.Y. Lau, Kitty K.Y. Wong, Nancy L.S. Chow, C.S. Lau, Edman T.K. Lam, Rickjason C.W. Chan, Dominic N.C. Tsang, Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2, Journal of Clinical Virology, Volume 134, 2021, 104712, ISSN 1386-6532, https://doi.org/10.1016/j.jcv.2020.104712.
9: Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, Ackerman R, Cooper CK. 2021. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-ofcare test. J Clin Microbiol 59:e02338-20. https:// doi.org/10.1128/JCM.02338-20
10: Osterman, A., Baldauf, HM., Eletreby, M. et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Med Microbiol Immunol 210, 65–72 (2021). https://doi.org/10.1007/s00430-020-00698-8
11. Labcorp EUA – Histogram of Cts, https://www.fda.gov/media/136151/download
12: Andrew Pekosz et al., Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture, Clinical Infectious Diseases, 2021;, ciaa1706, https://doi.org/10.1093/cid/ciaa1706
Supporting healthier lives, for individuals, communities and wider society
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.